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Primary Conjunctival Follicular Lymphoma Treated with the Anti-CD20 
Antibody Rituximab and Low-Dose Involved Field Radiotherapy 
 
Follicular lymphoma (FL) originating in the ocular adnexa is rarely reported, and curative 
radiotherapy for it is still questionable. Herein, we report a case of primary FL treated with 




A 67-year-old Japanese male patient was referred with a 2-month history of a progressive tumor 
in the conjunctiva of his right eye (Fig. 1a, b). A tumor sample was obtained by incisional 
biopsy. By histopathological analysis, it was found to consist of proliferated medium-sized 
atypical centrocytic lymphoid cells, forming a follicular nodule (Fig. 2a, c). Large centroblastic 
cells were very few in the nodule (Fig. 2c). The lymphoid cells showed positive 
immunoreactivity for CD20, CD79α, CD10, bcl-6 (Fig. 2d), and bcl-2 (Fig. 2e) Polymerase 
chain reaction (PCR) using the tumor DNA detected a fusion product of the major breakpoint 
region of the bcl-2 gene and IgH J region1 (Fig. 2f). Based on these findings, the lesion was 
diagnosed as a follicular lymphoma (FL) grade 1, according to the World Health Organization 
classification (2001). Consecutive general examinations (including whole-body computed 
tomography, and Ga-scintigraphy) did not detect any other primary or metastatic lesions. One 
month after the initial visit, a similar lesion appeared in the conjunctiva of the left eye of the 
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patient (Fig. 1c), and also proved to be an FL grade 1 by an additional biopsy (Fig. 2b) and 
immunohistochemical studies.  
The patient underwent anti-CD20 antibody therapy (rituximab, 375 mg/m2 intravenously 
once weekly for 4 weeks), and the lesions decreased in size gradually. Subsequently, LD-IF-RT 
with a regimen of 2 days of 2 Gy X- ray (4 Gy total) for both orbital regions was performed. 
The conjunctival lesions in both eyes diminished approximately one month after the LD-IF-RT 




Primary conjunctival FL is very rare. RT-PCR was useful to detect a t(14;18) (q32;q21) 
translocation 1 from a very small sample of the conjunctival lesion. Until several years ago, the 
management of FL was basically palliative. Recently, the efficacy of rituximab therapy for 
follicular lymphoma was evaluated. In a few clinical trials using rituximab alone for untreated 
follicular lymphomas, response rates ranged between 61% and 80 %.2  So far, only one case of 
conjunctival follicular lymphoma treated with rituximab alone was reported.3  However, the 
evidence for diagnosis was not shown and the follow-up period was only 5 months.3 Generally, 
the common side effects of rituximab are not severe, and include fever, chill and nausea. No 
side effect of rituximab was observed in this case. 
Radiotherapy with curative intent for early stage follicular lymphoma is still questionable 
because of the recurrence rate of approximately 50% and the treatment side effects. LD-IF-RT 
(2 x 2 Gy regimen) was initially applied to treat recurrences of advanced follicular lymphoma. 
Recent studies showed high response rates (>80 %) in indolent lymphoma patients.4  We 
combined rituximab therapy and LD-IF-RT, since it is too early to evaluate the efficacy of each 
of them on survival. Minimizing radiation-induced disorders of eyes, i.e., cataract, was also 
another reason to select LD-IF-RT. As it happens, this therapeutic idea is supported by a recent 
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study showing that pretreatment with rituximab enhances the radiosensitivity of non-Hodgkin's 
lymphoma cells.5 
In conclusion, for early stage conjunctival follicular lymphoma, the combination of anti-
CD20 antibody therapy and LD-IF-RT may be an alternative therapy.  
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Figure Legends 
 
Figure 1. Conjunctival tumor before and after the treatment with rituximab and low-dose  involved 
field radiotherapy (a, b). Anterior segment photos show follicular tumor in the 
conjunctiva of the right eye at the initial visit. (c) Follicular lesion (arrowheads) 
appeared in the conjunctiva of the left eye one month after the initial visit. (d) The 
tumor in the right eye diminished two months after treatment.  
 
Figure 2a - f.  (a) A light microscopic image of the tumor in the conjunctiva of the right eye. A 
follicular or nodular lymphoid aggregation is seen in the conjunctival submucosa. 
The follicles lack tangible (tangible means “can be touched – or seen”  How 
about “visible”?) ANSW: “tangible-body macropharge” (TBM) is a specific word 
in histopathological field. Please do not change. body macrophages and cellular 
polarization. Mantle zone is very thin (arrows) or inconspicuous because of the 
expansion of the follicular center cells. H-E staining, scale bar = 500 μm. (b) One 
month later, a tumor appeared in the conjunctiva of the left eye, also showing 
follicular proliferation of lymphocytes. H-E staining, scale bar = 500 μm. (c) 
Higher magnification of the follicular center of the conjunctival tumor in the right 
eye. The cells consist mostly of small cleaved centrocyte-like cells. Large 
centroblastic cells are very few. H-E staining, scale bar = 20 μm. (d) 
Immunostaining of bcl-6 in the conjunctival tumor in the right eye. The follicle 
center shows diffuse nuclear staining for bcl-6. Scale bar = 500 μm. (e) 
Immunostaining of bcl-2 in the conjunctival tumor in the right eye. The follicle 
center shows diffuse cytoplasmic staining for bcl-2. Scale bar = 500 μm. (f) The 
tumor DNA was amplified between the V-region of IgH (immunoglobulin heavy 
chain) (lane 1), a major breakpoint region (mbr) (lane 2), or a minor cluster region 
(mcr) (lane 3) of the bcl-2 gene and the consensus J region of IgH1. A band 
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indicated by an asterisk (lane 2) was confirmed to contain the bcl-2 sequence by 






TCATGGCTGTCCTTCAGGGTCTTCCTGAAATGCAGTGGTGC. Other bands 
were not specific. M: size marker lane.  
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